Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/YASNAL 10 mg COMPRIMIDOS BUCODISPERSABLES EFG

Approved

STANDARD

YASNAL 10 mg COMPRIMIDOS BUCODISPERSABLES EFG

Krka D.D. Novo Mesto🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Nov 11, 2021
Approval ID: 9d2b6096903d7e8a
Company: Krka D.D. Novo Mesto
Type: Standard

Approval Details

Approval Id: 9d2b6096903d7e8a
Drug Cima Aemps Name: YASNAL 10 mg COMPRIMIDOS BUCODISPERSABLES EFG
Register Number: 9933
Holder Company Name: Krka D.D. Novo Mesto
Marketing Company Name: Elam Pharma Labs S.L.
Authorization Date: 2021-11-11
Dosage Form: COMPRIMIDO BUCODISPERSABLE
Dose: 10 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: No
Company Name: Krka D.D. Novo Mesto

Active Ingredients

DONEPEZILO HIDROCLORURO

10 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Nov 11, 2021

Approval ID

9d2b6096903d7e8a

Type

Standard

Back to CIMA-AEMPS Approvals

YASNAL 10 mg COMPRIMIDOS BUCODISPERSABLES EFG - CIMA-AEMPS Drug Approval Details